Email Updates

Place quotation marks around exact phrases (e.g. "new york"). Note: Trial names have a space before the number (e.g. HVTN 100).

You are here

Home

Trial Search

Trial Name Prevention Option Phase Start Date Sponsors Countries Population Candidate(s) Status
PROMISE-EPI Combination Prevention Open Label December 2019 ANRS, Emerging Infectious Diseases Burkina Faso, Zambia Women Lamivudine Ongoing
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults Treatment I November 2018 Gilead Sciences United States of America Men Lenacapavir Completed
CALIBRATE Combination Prevention Open Label, II November 2019 Gilead Sciences Men, Women F/TAF, Lenacapavir , tenofovir, emtricitabine
PURPOSE 1 Combination Prevention III August 2021 Gilead Sciences South Africa Women F/TAF, Lenacapavir , F/TDF Paused
CAPELLA Combination Prevention III, II November 2019 Gilead Sciences United States of America, France, Italy, South Africa, Spain, Thailand, Canada, Dominican Republic, Germany, Japan, Taiwan HIV positive, Men, Women Lenacapavir Ongoing
PURPOSE 2 PrEP III June 2021 Gilead Sciences United States of America Men, MSM, Transgender men, Transgender women Lenacapavir , F/TDF Paused
Study to Evaluate the Safety and Efficacy of GS-5423 and GS-2872 in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection Combination Prevention I March 2021 Gilead Sciences United States of America Men, Women Lenacapavir Ongoing
IAVI G002 HIV Vaccine I August 2021 International AIDS Vaccine Initiative; ModernaTX, Inc.; The University of Texas at San Antonio; George Washington University; Fred Hutchinson Cancer Research Center; Emory University Men, Women Ongoing
Impower-024 PrEP III March 2021 Merck Sharp & Dohme Corp. Men, MSM, Transgender women Islatravir (MK-8591) Paused
Impower 022 PrEP III February 2021 Merck Sharp & Dohme Corp. United States of America, South Africa Women Islatravir (MK-8591), TDF/FTC (Truvada) Paused
SSPN formulations of novel emtricitabine PrEP Pre-clinical emtricitabine
Transdermal Delivery System for Tenofovir Alafenamide PrEP Pre-clinical Eastern Virginia Medical School, CONRAD, Corporation of Mercer University, USAID/PEPFAR F/TAF Stopped Early
CAPRISA 018 PrEP I January 2017 Centre for the Aids Programme of Research in South Africa; Stichting Amsterdam Institute for Global Health and Development; Université Jean Monnet, Saint-Etienne Women tenofovir Ongoing
90-day Pod-type Etonogestrel/Ethinyl Estradiol/QGriffithsin (QGRFT) Intravaginal Ring [EEQ IVR] Microbicides Pre-clinical April 2020 NIAID Q-GRFT Ongoing
Mucosal insert containing TAF and EVG Pre-clinical CDC TAF/EVG
Islatravir (EFdA) + Etonogestrel/Ethinyl Estradiol 3D Printed IVR Microbicides Pre-clinical December 2019 Men Islatravir (MK-8591)
Innovative 3D Printed Intravaginal Rings Microbicides Pre-clinical August 2018 Men Dapivirine-Levonorgestrel ring
Amphora/QGriffithsin (QGRFT) fast-dissolving vaginal insert (FDI) Microbicides Pre-clinical May 2021 NIAID Q-GRFT
mAb 2C7 + TDF IVR Microbicides Open Label April 2018 Men TDF Ongoing
Novel mAb contraceptive + TDF IVR Microbicides Pre-clinical May 2020 NICHD TDF Ongoing

Pages

CSVDoc